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Background
Angina which is refractory to conventional medical ther-
apy and revascularisation with bypass surgery and/or
percutaneous coronary intervention is extremely chal-
lenging to manage with limited treatment options and a
pressing need to establish effective therapy.
Lipoprotein(a) [Lp(a)], a genetically determined form
of LDL-cholesterol, is an independent cardiovascular
risk factor which is felt to increase risk by promoting
thrombosis; enhancing intimal lipoprotein deposition,
and by potentially affecting myocardial perfusion, micro-
vascular function, plasma viscosity and endothelial func-
tion. Lipoprotein apheresis is currently the most effective
treatment available for raised Lp(a). Increasing evidence
suggests that aggressive Lp(a) reduction may improve
cardiovascular outcomes, although much more prospec-
tive research is required to confirm this.
Methods
We are conducting a prospective, blinded randomised con-
trolled cross-over study of patients with refractory angina
and raised Lp(a), randomised to undergoing lipoprotein
apheresis or ‘sham’ apheresis with assessment of the impact
of treatment on myocardial perfusion, carotid atherosclero-
sis, endothelial function, thrombogenesis, oxidised phos-
pholipids, exercise capacity, angina and quality of life.
Our primary hypothesis is that lipoprotein apheresis
improves quantitative myocardial perfusion assessed by
Myocardial Perfusion Reserve (MPR) detected by stress/
rest Cardiovascular Magnetic Resonance (CMR), in
patients with refractory angina and raised Lp(a).
At least 20 patients with refractory angina and elevated
Lp(a) will be recruited and randomly assigned to either a
treatment arm who will undergo lipoprotein apheresis
weekly for three months, or to a control group who will
receive placebo ‘sham’ sessions weekly for three months.
All patients will have CMR at baseline assessing func-
tional parameters, first-pass quantitative perfusion at
stress and rest and late gadolinium enhancement (LGE),
and quantitative assessment of carotid atherosclerosis.
Following the three month period of either active or
sham therapy all baseline tests will be repeated to deter-
mine the net treatment effect. After a wash-out period of
at least 1 month, patients will cross-over to the opposite
treatment arm with the process repeated.
Results
The trial is currently in progress. Analysis of quantita-
tive myocardial perfusion and carotid indices will be
performed fully blinded with results expected by the end
of 2015.
Conclusions
We are conducting a randomised controlled cross-over
trial using CMR to assess whether lipoprotein apheresis
is beneficial in patients with refractory angina and raised
Lp(a). Our research will confirm whether raised Lp(a)
should be a therapeutic target in patients with refractory
angina and will provide valuable insights into the
mechanistic role of Lp(a) in cardiovascular disease.
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